Risk of major bleeding in unselected patients with venous thromboembolism

Blood Coagulation and Fibrinolysis

Volumn 11, Issue 2, 2000, Pages 199-202

  Bigaroni, A ^a   Perrier, A ^b   De Moerloose, P ^a   Perneger, T ^a   Bounameaux, H ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b Medical Clinic   (Switzerland)

Author keywords

Anticoagulant therapy; Bleeding; Deep vein thrombosis; Pulmonary embolism

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

AGED; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMORBIDITY; DEEP VEIN THROMBOSIS; DRUG MONITORING; FEMALE; HEPARINIZATION; HUMAN; LUNG EMBOLISM; MALE; PRIORITY JOURNAL; RISK; THROMBOEMBOLISM;

EID: 0033999784     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001721-200003000-00012     Document Type: Article

References (15)

1. 1. Hyers TM, Agnelli G, Hull RD, Weg JG, Morris TA, Samama M, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 1998, 114(suppl 5): 561-578.
2. 2. Laupacis A, Albers GW, Dalen JE, Horstkotte D, Turpie AG. Antithrombotic therapy in atrial fibrillation. Chest 1998, 114(suppl 5): 579-589.
3. 3. Salem DN, Levine HJ, Pauker SG, Eckman MH, Daudelin DH. Antithrombotic therapy in valvular heart disease. Chest 1998, 114(suppl 5): 590-601.
4. 4. Levine M, Raskob GE, Landefeld CS, Kearon C. Hemorrhagic complications of anticoagulant therapy. Chest 1998, 114(suppl 5): 511-523.
5. 5. Perrier A, Desmarais S, Goehring C, de Moerloose P, Morabia A, Unger PF, et al. D-Dimer testing for suspected pulmonary embolism. Am J Resp Crit Care Med 1997; 156: 492-496.
6. 6. Perrier A, Desmarais S, Miron MJ, de Moerloose P, Lepage R, Slosman L, et al. Non-invasive diagnosis of venous thromboembolism in outpatients. Lancet 1999; 353: 190-195.
7. 7. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
8. 8. Fihn SD, McDonnel M, Martin D, Henikoff J, Vermes D, Kent D, et al. Risk factors for complications of chronic anticoagulation: a multi-centre study. Ann Intern Med 1993; 118: 511-520.
9. 9. Landefeld CS, Goldman L. Major bleeding in outpatients treated with warfarin: incidence and prediction by factors known at the start of outpatient therapy. Am J Med 1989, 87: 144-152.
10. 10. Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D'Angelo A, et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Lancet 1996; 348: 423-428.
11. 11. Forfar JC. A 7-year analysis of hemorrhage in patients in long-term anticoagulant treatment. Br Heart J 1979; 42: 128-132.
12. 12. Lundstrom T, Ryden L. Hemorrhagic and thromboembolic complications in patients with atrial fibrillation on anticoagulant prophylaxis. J Intern Med 1989; 225: 137-142.
13. 13. Hull R, Hirsh J, Jay R, Carter C, England C, Gent M, et al. Different intensities of oral anticoagulant therapy in the treatment of proximal-vein thrombosis. N Engl J Med 1982; 307: 1676-1681.
14. 14. Hylek E, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994; 120: 897-902.
15. 15. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Aging and heparin-related bleeding. Arch Intern Med 1996; 156: 857-860.